GSK2256098
GSK2256098 is a tablet that blocks an enzyme called FAK, which meningiomas missing the NF2 gene rely on. In the Alliance A071401 trial it slowed progression in recurrent NF2-mutant meningiomas, one of the first positive results for a targeted drug in this tumour.
Overview
GSK2256098 is a small-molecule inhibitor of focal adhesion kinase developed by GSK. Loss of NF2 (merlin), the commonest driver in meningioma, makes cells dependent on FAK signalling for growth on and adhesion to their matrix, which preclinical work showed could be exploited.
In Alliance A071401, a genomically guided phase 2 trial that assigns progressive meningiomas to drugs by mutation, the FAK-inhibitor arm for NF2-mutant tumours met its progression-free survival endpoint: six-month progression-free survival was 83 percent for grade 1 and 33 percent for grade 2 to 3 tumours, with good tolerability (Journal of Clinical Oncology, 2023). The meningioma page names it as the first mutation-matched treatment to show activity in the disease.
- ATP pocket
- Inhibitor blocks phosphotransfer
- Kinase domain
An ATP-competitive inhibitor of focal adhesion kinase; meningiomas that have lost the NF2 tumour suppressor merlin depend on FAK signalling, so blocking it is a synthetic-lethal approach to NF2-mutant tumours.
1.GSK2256098 slips into a pocket on its target.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"GSK2256098" OR ABSTRACT:"GSK2256098" OR TITLE:"GSK-2256098" OR ABSTRACT:"GSK-2256098") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GSK2256098, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentMifepristone
Shares Meningioma and the tag subtype-drugs-wave.
- TreatmentCediranib
Shares Small-molecule kinase inhibitors and the tag subtype-drugs-wave.
- TreatmentMomelotinib
Shares GSK, Small-molecule kinase inhibitors.